查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1370956

栓塞治疗市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按产品、适应症、程序、最终用户、地区和竞争细分

Embolotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product, By Indication, By Procedure, By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 189 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年全球栓塞治疗市场估值为 36.7 亿美元，预计在预测期内将大幅成长，年复合成长率(CAGR) 为 8.35%，预计到 2028 年将达到 59.9 亿美元。选择性地限制血液流向特定区域的侵入性治疗正在全球获得认可和普及。这种血管内手术用于闭塞异常血管，有效控製或止血。在严重出血的紧急情况下，栓塞疗法正成为侵入性手术的可行替代方案，特别是对于严重出血等情况。介入放射科医师在各种临床环境中执行此程序。栓塞疗法的应用已显着扩大，特别是在用于治疗良性前列腺增生的前列腺动脉栓塞术（PAE）和用于减肥的胃动脉栓塞术（GAE）等尖端手术中。这些程序已被证明可以有效治疗各自的病症。例如，全球范围内进行 PAE 治疗，以解决 BPH 引起的下泌尿道症状 (LUTS)，每年进行 800 多例手术。栓塞疗法也用于治疗慢性疼痛、治疗子宫肌瘤以及治疗特定类型的癌症，例如肝癌。

主要市场驱动因素

不断增长的目标患者群体

市场概况
预测期 2024-2028
2022 年市场规模 36.7亿美元
2028 年市场规模 59.9亿美元
2023-2028 年CAGR 8.35%
成长最快的细分市场 栓塞剂
最大的市场 北美洲

心血管疾病（CVD）的流行和成功治疗的重要性日益增加，导致人们开始关注有效干预措施的研究。 2017年，週边血管疾病影响了全球超过2亿人。随着年龄的增长，这些疾病的盛行率不断上升，尤其是在80岁及以上的老年人中。对栓塞治疗设备的需求是由其成功率、术后併发症低以及肝癌和肝细胞癌等疾病发病率上升所推动的。肝癌是男性和女性最常见的癌症之一，2018 年全球新诊断病例超过 84 万例。肾癌发生率也有所增加，特别是在英国。这些趋势增加了对栓塞疗法的需求。

患者对微创手术的偏好不断上升

人们对微创手术的日益青睐正在推动对栓塞疗法等手术的需求。患者选择这些手术是因为术后疼痛减轻、併发症更少、住院时间更短、恢復时间更快。经动脉化疗栓塞 (TACE) 等技术正在作为微创替代方案不断发展，彻底改变了肝细胞癌等治疗方法。摄护腺动脉栓塞术（PAE）是治疗良性摄护腺增生（BPH）及其相关症状的微创疗法。人们对这些手术的日益青睐正在扩大栓塞治疗市场。

政府和私人组织的资助和投资

充足的资金和投资推动了栓塞疗法等医疗程序的研究、开发和改进。积极的试验结果给医疗专业人员和患者带来了信心，推动了采用的需求。培训计划和医学教育向专业人员传播知识，导致需求增加。政府的资助和支持影响保险范围和报销政策，使栓塞治疗更容易获得。

栓塞治疗设备的技术进步

栓塞治疗设备的技术进步提高了精确度、有效性和微创品质。增强型微导管、先进的影像技术、导航系统、机器人和视觉化工具已经改变了这个领域。这些进步改善了手术结果、病人安全和恢復时间。随着技术的发展，栓塞治疗领域可能会看到进一步的创新来增强这些程序。

主要市场挑战

严格的规定

人工栓塞装置被归类为医疗器械，并受到严格的监管。监管分类影响器械审批和授权，进而影响市场格局。

缺乏熟练的医疗专业人员

缺乏熟练的专业人员可能会限制栓塞疗法的获得，影响患者的治疗结果并增加风险。

主要市场趋势

增加收购和合作

合作增强了栓塞治疗的研究、开发、可近性和意识。协作努力加速创新和针对不同患者需求量身定制的解决方案。

肿瘤学进展

创新癌症治疗的需求推动了对栓塞疗法等个人化解决方案的需求。精确性和微创性使栓塞疗法在个人化肿瘤护理中具有吸引力。

细分市场洞察

产品洞察

由于需要微球的疾病越来越普遍，特别是在肝细胞癌治疗中，栓塞剂领域占据了市场主导地位。

最终使用者见解

医院是栓塞治疗设备的主要使用者。微创手术的使用不断增加、医疗保健提供者的购买力不断增强以及报销的可用性有助于该细分市场的成长。

区域洞察

北美洲

由于需要栓塞治疗的疾病普遍存在、完善的医疗保健系统以及栓塞剂的不断进步，北美在市场上处于领先地位。

亚太

由于患者人数增加、政府医疗投资和癌症发病率上升，亚太地区预计将经历最快的增长。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球栓塞治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 副产品（栓塞剂、微导管）
    • 依适应症（肿瘤科、血管科、动脉瘤科、泌尿科、肾臟科）
    • 按程序（TACE、TARE）
    • 按最终使用者（医院、诊所、门诊手术中心）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图

第 6 章：北美栓塞治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 按指示
    • 按程式
    • 按最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲栓塞治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 按指示
    • 按程式
    • 按最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第 8 章：亚太地区栓塞治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 按指示
    • 按程式
    • 按最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 9 章：南美洲栓塞治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 按指示
    • 按程式
    • 按最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲栓塞治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 按指示
    • 按程式
    • 按最终用户
    • 按国家/地区
  • MEA：国家分析
    • 南非栓塞疗法
    • 沙乌地阿拉伯栓塞疗法
    • 阿联酋栓塞疗法

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 近期发展
  • 併购
  • 产品发布

第 13 章：全球口腔临床营养市场：SWOT 分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第15章：竞争格局

  • 商业概览
  • 服务内容
  • 最近的发展
  • 主要人员
  • SWOT分析
    • Medtronic, PLC
    • Microport Scientific
    • Boston Scientific Corporation
    • Stryker
    • Terumo Corporation
    • Penumbra, Inc.
    • Sirtex (CDH)
    • Johnson & Johnson
    • Abbott Laboratories
    • Balt Group

第 16 章：策略建议

第 17 章：关于我们与免责声明

简介目录
Product Code: 4666

The Global Embolotherapy Market was valued at USD 3.67 Billion in 2022 and is expected to experience substantial growth in the forecast period, with a Compound Annual Growth Rate (CAGR) of 8.35% and expected to reach USD 5.99 Billion through 2028. Embolotherapy, a minimally invasive treatment that selectively restricts blood flow to specific areas, is gaining recognition and popularity globally. This endovascular procedure is utilized to occlude abnormal blood vessels, effectively controlling or stopping bleeding. In urgent cases of severe hemorrhage, Embolotherapy is emerging as a viable alternative to invasive surgery, particularly for cases like severe bleeding. Interventional radiologists perform this procedure in various clinical settings. The applications of Embolotherapy have expanded significantly, especially in cutting-edge procedures like prostatic artery embolization (PAE) for benign prostatic hyperplasia and gastric artery embolization (GAE) for weight loss. These procedures have proven to be effective in treating their respective conditions. For instance, PAE is performed globally to address lower urinary tract symptoms (LUTS) caused by BPH, with over 800 procedures annually. Embolotherapy is also used in managing chronic pain conditions, treating uterine fibroids, and addressing specific types of cancer, such as liver cancer.

Key Market Drivers

Growing Target Patient Population

Market Overview
Forecast Period2024-2028
Market Size 2022USD 3.67 Billion
Market Size 2028USD 5.99 Billion
CAGR 2023-20288.35%
Fastest Growing SegmentEmbolic Agents
Largest MarketNorth America

The prevalence of cardiovascular disease (CVD) and the increasing importance of successful treatments have led to a focus on research into effective interventions. Peripheral vascular diseases affected over 200 million individuals globally in 2017. With age, the prevalence of these diseases rises, particularly in those aged 80 and above. The demand for Embolotherapy devices is driven by its success rate, low postoperative complications, and the rising incidence of conditions like liver cancer and hepatocellular cancer. Liver cancer is among the most common cancers in men and women, with over 840,000 new cases diagnosed worldwide in 2018. Kidney cancer incidence rates have also increased, particularly in the United Kingdom. These trends contribute to the demand for Embolotherapy.

Rising Patient Preference for Minimally Invasive Procedures

The increasing preference for minimally invasive surgeries is driving the demand for procedures like Embolotherapy. Patients opt for these procedures due to reduced postoperative pain, fewer complications, shorter hospital stays, and faster recovery times. Techniques like Trans Arterial Chemo Embolization (TACE) are evolving as minimally invasive alternatives, revolutionizing treatments like hepatocellular carcinoma. Prostatic Artery Embolization (PAE) serves as a minimally invasive therapy for benign prostatic hyperplasia (BPH) and its associated symptoms. The growing preference for these procedures is expanding the embolotherapy market.

Funding & Investments by Government and Private Organizations

Adequate funding and investments drive research, development, and refinement of medical procedures like Embolotherapy. Positive trial results instill confidence in medical professionals and patients, driving demand for adoption. Training programs and medical education disseminate knowledge among professionals, leading to increased demand. Government funding and support influence insurance coverage and reimbursement policies, making Embolotherapy more accessible.

Technological Advancements in Embolotherapy Devices

Technological advancements in embolotherapy devices have improved precision, effectiveness, and minimally invasive qualities. Enhanced microcatheters, advanced imaging techniques, navigation systems, robotics, and visualization tools have transformed the field. These advancements improve procedural outcomes, patient safety, and recovery times. As technology evolves, the embolotherapy field will likely see further innovations enhancing these procedures.

Key Market Challenges

Stringent Regulations

Artificial embolization devices are classified as medical devices and are subject to stringent regulations. Regulatory classifications impact device approval and authorization, influencing the market landscape.

Lack Of Skilled Medical Professionals

A shortage of skilled professionals can limit access to embolotherapy treatments, affecting patient outcomes and increasing risks.

Key Market Trends

Increasing Acquisitions and Collaborations

Collaborations enhance research, development, accessibility, and awareness of embolotherapy. Collaborative efforts accelerate innovation and solutions tailored to diverse patient needs.

Advancement in Oncology

The need for innovative cancer treatments drives demand for personalized solutions like embolotherapy. Precision and minimal invasiveness make embolotherapy attractive in personalized oncology care.

Segmental Insights

Product Insights

The embolic agent segment dominates the market due to the increasing prevalence of conditions requiring microspheres, especially in hepatocellular carcinoma treatment.

End User Insights

Hospitals are the primary users of embolotherapy devices. The increasing utilization of minimally invasive procedures, growing healthcare provider purchasing power, and availability of reimbursements contribute to this segment's growth.

Regional Insights

North America

North America leads the market due to the prevalence of conditions requiring embolization, a well-established healthcare system, and ongoing advancements in embolic agents.

Asia-Pacific

The Asia-Pacific region is expected to experience the fastest growth due to increasing patient populations, government healthcare investments, and rising cancer incidence.

Key Market Players

  • Medtronic, PLC
  • Microport Scientific
  • Boston Scientific Corporation
  • Stryker
  • Terumo Corporation
  • Penumbra, Inc.
  • Sirtex (CDH)
  • Johnson & Johnson
  • Abbott Laboratories
  • Balt Group

Report Scope:

In this report, the Global Embolotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Embolotherapy Market, By Product:

  • Embolic Agents
  • Microspheres
  • Liquid Embolic Agents
  • Coil
  • Microcatheters

Embolotherapy Market, By Indication:

  • Oncology
  • Vascular
  • Aneurysm
  • Urology
  • Nephrology

Embolotherapy Market, By Procedure:

  • TACE
  • TARE

Embolotherapy Market, By End User:

  • Hospital
  • Clinics
  • Ambulatory Surgery Centres

Embolotherapy Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Embolotherapy Market.

Available Customizations:

  • Global Embolotherapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Embolotherapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Embolic Agents, Microcatheters)
      • 5.2.1.1. By Embolic Agents (Microspheres, Liquid Embolic Agents, Coil)
    • 5.2.2. By Indication (Oncology, Vascular, Aneurysm, Urology, Nephrology)
    • 5.2.3. By Procedure (TACE, TARE)
    • 5.2.4. By End User (Hospital, Clinics, Ambulatory Surgery Centres)
    • 5.2.5. By Region
    • 5.2.6. By Company (2022)
  • 5.3. Market Map

6. North America Embolotherapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
      • 6.2.1.1. By Embolic Agents
    • 6.2.2. By Indication
    • 6.2.3. By Procedure
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Embolotherapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.1.1. By Embolic Agents
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By Procedure
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Embolotherapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.1.1. By Embolic Agents
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By Procedure
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Embolotherapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.1.1. By Embolic Agents
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By Procedure
        • 6.3.3.2.4. By End User

7. Europe Embolotherapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
      • 7.2.1.1. By Embolic Agents
    • 7.2.2. By Indication
    • 7.2.3. By Procedure
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Embolotherapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.1.1. By Embolic Agents
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Procedure
        • 7.3.1.2.4. By End User
    • 7.3.2. United Kingdom Embolotherapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.1.1. By Embolic Agents
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Procedure
        • 7.3.2.2.4. By End User
    • 7.3.3. Italy Embolotherapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Product
        • 7.3.3.2.1.1. By Embolic Agents
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Procedure
        • 7.3.3.2.4. By End User
    • 7.3.4. France Embolotherapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.1.1. By Embolic Agents
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By Procedure
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Embolotherapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.1.1. By Embolic Agents
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By Procedure
        • 7.3.5.2.4. By End User

8. Asia-Pacific Embolotherapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
      • 8.2.1.1. By Embolic Agents
    • 8.2.2. By Indication
    • 8.2.3. By Procedure
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Embolotherapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.1.1. By Embolic Agents
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Procedure
        • 8.3.1.2.4. By End User
    • 8.3.2. India Embolotherapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.1.1. By Embolic Agents
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Procedure
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Embolotherapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.1.1. By Embolic Agents
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Procedure
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Embolotherapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.1.1. By Embolic Agents
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Procedure
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Embolotherapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.1.1. By Embolic Agents
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Procedure
        • 8.3.5.2.4. By End User

9. South America Embolotherapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
      • 9.2.1.1. By Embolic Agents
    • 9.2.2. By Indication
    • 9.2.3. By Procedure
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Embolotherapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.1.1. By Embolic Agents
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Procedure
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina Embolotherapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.1.1. By Embolic Agents
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Procedure
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia Embolotherapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.1.1. By Embolic Agents
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Procedure
        • 9.3.3.2.4. By End User

10. Middle East and Africa Embolotherapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
      • 10.2.1.1. By Embolic Agents
    • 10.2.2. By Indication
    • 10.2.3. By Procedure
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Embolotherapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.1.1. By Embolic Agents
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Procedure
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Embolotherapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.1.1. By Embolic Agents
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Procedure
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Embolotherapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.1.1. By Embolic Agents
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Procedure
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Oral Clinical Nutrition Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Service Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. Medtronic, PLC
    • 15.5.2. Microport Scientific
    • 15.5.3. Boston Scientific Corporation
    • 15.5.4. Stryker
    • 15.5.5. Terumo Corporation
    • 15.5.6. Penumbra, Inc.
    • 15.5.7. Sirtex (CDH)
    • 15.5.8. Johnson & Johnson
    • 15.5.9. Abbott Laboratories
    • 15.5.10. Balt Group

16. Strategic Recommendations

17. About Us & Disclaimer